» Articles » PMID: 22357655

Suppression of α-synuclein Toxicity and Vesicle Trafficking Defects by Phosphorylation at S129 in Yeast Depends on Genetic Context

Overview
Journal Hum Mol Genet
Date 2012 Feb 24
PMID 22357655
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The aggregation of α-synuclein (αSyn) is a neuropathologic hallmark of Parkinson's disease and other synucleinopathies. In Lewy bodies, αSyn is extensively phosphorylated, predominantly at serine 129 (S129). Recent studies in yeast have shown that, at toxic levels, αSyn disrupts Rab homeostasis, causing an initial endoplasmic reticulum-to-Golgi block that precedes a generalized trafficking collapse. However, whether αSyn phosphorylation modulates trafficking defects has not been evaluated. Here, we show that constitutive expression of αSyn in yeast impairs late-exocytic, early-endocytic and/or recycling trafficking. Although members of the casein kinase I (CKI) family phosphorylate αSyn at S129, they attenuate αSyn toxicity and trafficking defects by an S129 phosphorylation-independent mechanism. Surprisingly, phosphorylation of S129 modulates αSyn toxicity and trafficking defects in a manner strictly determined by genetic background. Abnormal endosome morphology, increased levels of the endosome marker Rab5 and co-localization of mammalian CKI with αSyn aggregates are observed in brain sections from αSyn-overexpressing mice and human synucleinopathies. Our results contribute to evidence that suggests αSyn-induced defects in endocytosis, exocytosis and/or recycling of vesicles involved in these cellular processes might contribute to the pathogenesis of synucleinopathies.

Citing Articles

RXR nuclear receptor signaling modulates lipid metabolism and triggers lysosomal clearance of alpha-synuclein in neuronal models of synucleinopathy.

Tripathi A, Alnakhala H, Brontesi L, Selkoe D, Dettmer U Cell Mol Life Sci. 2024; 81(1):362.

PMID: 39162859 PMC: 11336128. DOI: 10.1007/s00018-024-05373-2.


Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.

Prasanth M, Sivamaruthi B, Cheong C, Verma K, Tencomnao T, Brimson J Antioxidants (Basel). 2024; 13(5).

PMID: 38790711 PMC: 11118909. DOI: 10.3390/antiox13050606.


Positron Emission Tomography with [F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy.

Gallagher E, Hou C, Zhu Y, Hsieh C, Lee H, Li S Int J Mol Sci. 2024; 25(9).

PMID: 38732162 PMC: 11084161. DOI: 10.3390/ijms25094943.


Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.


Sporadic SNCA mutations A18T and A29S exhibit variable effects on protein aggregation, cell viability and oxidative stress.

Joshi N, Sarhadi T, Raveendran A, Nagotu S Mol Biol Rep. 2023; 50(7):5547-5556.

PMID: 37155014 DOI: 10.1007/s11033-023-08457-7.


References
1.
Luo Z, Gallwitz D . Biochemical and genetic evidence for the involvement of yeast Ypt6-GTPase in protein retrieval to different Golgi compartments. J Biol Chem. 2002; 278(2):791-9. DOI: 10.1074/jbc.M209120200. View

2.
Lafourcade C, Galan J, Gloor Y, Haguenauer-Tsapis R, Peter M . The GTPase-activating enzyme Gyp1p is required for recycling of internalized membrane material by inactivation of the Rab/Ypt GTPase Ypt1p. Mol Cell Biol. 2004; 24(9):3815-26. PMC: 387746. DOI: 10.1128/MCB.24.9.3815-3826.2004. View

3.
Mumberg D, Muller R, Funk M . Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression. Nucleic Acids Res. 1994; 22(25):5767-8. PMC: 310147. DOI: 10.1093/nar/22.25.5767. View

4.
van Ham T, Thijssen K, Breitling R, Hofstra R, Plasterk R, Nollen E . C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008; 4(3):e1000027. PMC: 2265412. DOI: 10.1371/journal.pgen.1000027. View

5.
Spillantini M, Goedert M . The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2001; 920:16-27. DOI: 10.1111/j.1749-6632.2000.tb06900.x. View